The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
IL-33 reduces the development of atherosclerosis
Open accessAbstract
Atherosclerosis is a chronic inflammatory disease of the vasculature commonly leading to myocardial infarction and stroke. We show that IL-33, which is a novel IL-1–like cytokine that signals via ST2, can reduce atherosclerosis development in ApoE−/− mice on a high-fat diet. IL-33 and ST2 are present in the normal and atherosclerotic vasculature of mice and humans. Although control PBS-treated mice developed severe and inflamed atherosclerotic plaques in the aortic sinus, lesion development was profoundly reduced in IL-33–treated animals. IL-33 also markedly increased levels of IL-4, -5, and -13, but decreased levels of IFNγ in serum and lymph node cells. IL-33 treatment also elevated levels of total serum IgA, IgE, and IgG1, but decreased IgG2a, which is consistent with a Th1-to-Th2 switch. IL-33–treated mice also produced significantly elevated antioxidized low-density lipoprotein (ox-LDL) antibodies. Conversely, mice treated with soluble ST2, a decoy receptor that neutralizes IL-33, developed significantly larger atherosclerotic plaques in the aortic sinus of the ApoE−/− mice compared with control IgG-treated mice. Furthermore, coadministration of an anti–IL-5 mAb with IL-33 prevented the reduction in plaque size and reduced the amount of ox-LDL antibodies induced by IL-33. In conclusion, IL-33 may play a protective role in the development of atherosclerosis via the induction of IL-5 and ox-LDL antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T. K., Zurawski, G., Moshrefi, M., Qin, J., Li, X., et al. (2005) · Immunity · doi:10.1016/j.immuni.2005.09.015 · Cited by 3,710
The immune response in atherosclerosis: a double-edged sword
Hansson, G. K., & Libby, P. (2006) · Nature Reviews Immunology · doi:10.1038/nri1882 · Cited by 2,182
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Tedgui, A., & Mallat, Z. (2006) · Physiological Reviews · doi:10.1152/physrev.00024.2005 · Cited by 1,701
Autoantibody against oxidised LDL and progression of carotid atherosclerosis
Salonen, J. T., Korpela, H., Salonen, R., Nyyssonen, K., Yla-Herttuala, S., Yamamoto, R., Butler, S., Palinski, W., & Witztum, J. L. (1992) · The Lancet · doi:10.1016/0140-6736(92)90926-t · Cited by 1,316
Natural regulatory T cells control the development of atherosclerosis in mice
Ait-Oufella, H., Salomon, B. L., Potteaux, S., Robertson, A.-K. L., Gourdy, P., Zoll, J., Merval, R., Esposito, B., Cohen, J. L., Fisson, S., et al. (2006) · Nature Medicine · doi:10.1038/nm1343 · Cited by 1,100
IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system
Sanada, S., Hakuno, D., Higgins, L. J., Schreiter, E. R., McKenzie, A. N. J., & Lee, R. T. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30634 · Cited by 1,044
Carriere, V., Roussel, L., Ortega, N., Lacorre, D.-A., Americh, L., Aguilar, L., Bouche, G., & Girard, J.-P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606854104 · Cited by 966
IFN-gamma potentiates atherosclerosis in ApoE knock-out mice.
Gupta, S., Pablo, A. M., Jiang, X. C., Wang, N., Tall, A. R., & Schindler, C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119465 · Cited by 868
Löhning, M., Stroehmann, A., Coyle, A. J., Grogan, J. L., Lin, S., Gutierrez-Ramos, J.-C., Levinson, D., Radbruch, A., & Kamradt, T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6930 · Cited by 605
Hörkkö, S., Bird, D. A., Miller, E., Itabe, H., Leitinger, N., Subbanagounder, G., Berliner, J. A., Friedman, P., Dennis, E. A., Curtiss, L. K., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci4533 · Cited by 559
Cited by
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
The immune system in atherosclerosis
Hansson, G. K., & Hermansson, A. (2011) · Nature Immunology · doi:10.1038/ni.2001 · Cited by 2,317
The interleukin-1 family: back to the future
Garlanda, C., Dinarello, C. A., & Mantovani, A. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.010 · Cited by 1,945
Immune and Inflammatory Mechanisms of Atherosclerosis
Galkina, E., & Ley, K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132620 · Cited by 1,437
Moussion, C., Ortega, N., & Girard, J.-P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003331 · Cited by 1,179
“Recently, studies in rodents indicated that IL-33 is expressed in the heart, by cardiac fibroblasts after mechanical stress [4] and by endothelial cells during atherosclerosis [12].”
BackgroundInterleukin-33 in health and disease
Liew, F. Y., Girard, J.-P., & Turnquist, H. R. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.95 · Cited by 1,147
Self-citationDisease-associated functions of IL-33: the new kid in the IL-1 family
Liew, F. Y., Pitman, N. I., & McInnes, I. B. (2010) · Nature Reviews Immunology · doi:10.1038/nri2692 · Cited by 1,003
Self-citationThe immunology of atherosclerosis
Gisterå, A., & Hansson, G. K. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.51 · Cited by 982
Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity
Brestoff, J. R., Kim, B. S., Saenz, S. A., Stine, R. R., Monticelli, L. A., Sonnenberg, G. F., Thome, J. J., Farber, D. L., Lutfy, K., Seale, P., et al. (2015) · Nature · doi:10.1038/nature14115 · Cited by 968
The IL-33/ST2 pathway: therapeutic target and novel biomarker
Kakkar, R., & Lee, R. T. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2660 · Cited by 794
Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases
Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., Klunker, S., Meyer, N., O’Mahony, L., Palomares, O., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.050 · Cited by 778
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
T cell subsets and functions in atherosclerosis
Saigusa, R., Winkels, H., & Ley, K. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0352-5 · Cited by 721
The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1
Cayrol, C., & Girard, J.-P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812690106 · Cited by 707
IL-33 is a crucial amplifier of innate rather than acquired immunity
Oboki, K., Ohno, T., Kajiwara, N., Arae, K., Morita, H., Ishii, A., Nambu, A., Abe, T., Kiyonari, H., Matsumoto, K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003059107 · Cited by 652
Interleukin-33 in tissue homeostasis, injury, and inflammation
Molofsky, A. B., Savage, A. K., & Locksley, R. M. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.006 · Cited by 638
The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases
Griesenauer, B., & Paczesny, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00475 · Cited by 619
The interleukin‐1 receptor/Toll‐like receptor superfamily: 10 years of progress
O'Neill, L. A. J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00701.x · Cited by 616
Recent Advances on the Role of Cytokines in Atherosclerosis
Ait-Oufella, H., Taleb, S., Mallat, Z., & Tedgui, A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207415 · Cited by 578
Macrophages as a therapeutic target to promote diabetic wound healing
Sharifiaghdam, M., Shaabani, E., Faridi-Majidi, R., De Smedt, S. C., Braeckmans, K., & Fraire, J. C. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.016 · Cited by 573
Saenz, S. A., Taylor, B. C., & Artis, D. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00713.x · Cited by 484
Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study
Wang, T. J., Wollert, K. C., Larson, M. G., Coglianese, E., McCabe, E. L., Cheng, S., Ho, J. E., Fradley, M. G., Ghorbani, A., Xanthakis, V., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.129437 · Cited by 482
Role of IL-33 in inflammation and disease
Miller, A. M. (2011) · Journal of Inflammation · doi:10.1186/1476-9255-8-22 · Cited by 481
Self-citationCytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets
Ramji, D. P., & Davies, T. S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.04.003 · Cited by 469
B cell depletion reduces the development of atherosclerosis in mice
Ait-Oufella, H., Herbin, O., Bouaziz, J.-D., Binder, C. J., Uyttenhove, C., Laurans, L., Taleb, S., Van Vré, E., Esposito, B., Vilar, J., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100155 · Cited by 469
Pichery, M., Mirey, E., Mercier, P., Lefrancais, E., Dujardin, A., Ortega, N., & Girard, J.-P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101977 · Cited by 466
Kurowska-Stolarska, M., Kewin, P., Murphy, G., Russo, R. C., Stolarski, B., Garcia, C. C., Komai-Koma, M., Pitman, N., Li, Y., McKenzie, A. N. J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4780 · Cited by 460
Self-citationMolecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 459
HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins
Bertheloot, D., & Latz, E. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.34 · Cited by 455
Molofsky, A. B., Van Gool, F., Liang, H.-E., Van Dyken, S. J., Nussbaum, J. C., Lee, J., Bluestone, J. A., & Locksley, R. M. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.019 · Cited by 431
McLaren, J. E., Michael, D. R., Ashlin, T. G., & Ramji, D. P. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.04.002 · Cited by 397
Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure
Rehman, S. U., Mueller, T., & Januzzi, J. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.042 · Cited by 386
Inflammation in atherosclerosis
Taleb, S. (2016) · Archives of Cardiovascular Diseases · doi:10.1016/j.acvd.2016.04.002 · Cited by 375
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline
Fu, A. K. Y., Hung, K.-W., Yuen, M. Y. F., Zhou, X., Mak, D. S. Y., Chan, I. C. W., Cheung, T. H., Zhang, B., Fu, W.-Y., Liew, F. Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604032113 · Cited by 369
Self-citationSeki, K., Sanada, S., Kudinova, A. Y., Steinhauser, M. L., Handa, V., Gannon;, J., & Lee, R. T. (2009) · Circulation: Heart Failure · doi:10.1161/circheartfailure.109.873240 · Cited by 365
Martínez, G. J., Celermajer, D. S., & Patel, S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.12.027 · Cited by 342
Jovanovic, I. P., Pejnovic, N. N., Radosavljevic, G. D., Pantic, J. M., Milovanovic, M. Z., Arsenijevic, N. N., & Lukic, M. L. (2014) · International Journal of Cancer · doi:10.1002/ijc.28481 · Cited by 328
Ali, S., Mohs, A., Thomas, M., Klare, J., Ross, R., Schmitz, M. L., & Martin, M. U. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003080 · Cited by 324
Interleukin-33 Induces Protective Effects in Adipose Tissue Inflammation During Obesity in Mice
Miller, A. M., Asquith, D. L., Hueber, A. J., Anderson, L. A., Holmes, W. M., McKenzie, A. N., Xu, D., Sattar, N., McInnes, I. B., & Liew, F. Y. (2010) · Circulation Research · doi:10.1161/circresaha.110.218867 · Cited by 324
Self-citationThe role of cytokines in the development of atherosclerosis
Fatkhullina, A. R., Peshkova, I. O., & Koltsova, E. K. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916110134 · Cited by 323
The Biology of ST2: The International ST2 Consensus Panel
Pascual-Figal, D. A., & Januzzi, J. L. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.01.034 · Cited by 319
Interleukin-33 – cytokine of dual function or novel alarmin?
Haraldsen, G., Balogh, J., Pollheimer, J., Sponheim, J., & Küchler, A. M. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.03.003 · Cited by 308
Jiang, H., Milovanović, M., Allan, D., Niedbala, W., Besnard, A., Fukada, S. Y., Alves‐Filho, J. C., Togbe, D., Goodyear, C. S., Linington, C., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201141947 · Cited by 307
Self-citationChoi, Y.-S., Choi, H.-J., Min, J.-K., Pyun, B.-J., Maeng, Y.-S., Park, H., Kim, J., Kim, Y.-M., & Kwon, Y.-G. (2009) · Blood · doi:10.1182/blood-2009-02-203372 · Cited by 302
Roussel, L., Erard, M., Cayrol, C., & Girard, J. (2008) · EMBO reports · doi:10.1038/embor.2008.145 · Cited by 300
The role of B cells in atherosclerosis
Sage, A. P., Tsiantoulas, D., Binder, C. J., & Mallat, Z. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0106-9 · Cited by 298
Inflammation and immune system interactions in atherosclerosis
Legein, B., Temmerman, L., Biessen, E. A. L., & Lutgens, E. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1289-1 · Cited by 292
RETRACTED: The cytokine interleukin-33 mediates anaphylactic shock
Pushparaj, P. N., Tay, H. K., H'ng, S. C., Pitman, N., Xu, D., McKenzie, A., Liew, F. Y., & Melendez, A. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901206106 · Cited by 285
Self-citationRetractedAllen, J. E., & Sutherland, T. E. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.06.003 · Cited by 263
IL-33/ST2 axis in inflammation and immunopathology
Milovanovic, M., Volarevic, V., Radosavljevic, G., Jovanovic, I., Pejnovic, N., Arsenijevic, N., & Lukic, M. L. (2012) · Immunologic Research · doi:10.1007/s12026-012-8283-9 · Cited by 256
Ballak, D. B., Stienstra, R., Tack, C. J., Dinarello, C. A., & van Diepen, J. A. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.005 · Cited by 255
Interleukin-33 overexpression is associated with liver fibrosis in mice and humans
Marvie, P., Lisbonne, M., L’Helgoualc’h, A., Rauch, M., Turlin, B., Preisser, L., Bourd‐Boittin, K., Théret, N., Gascan, H., Piquet‐Pellorce, C., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00801.x · Cited by 251
IL-33 and IL-33 receptors in host defense and diseases
Oboki, K., Ohno, T., Kajiwara, N., Saito, H., & Nakae, S. (2010) · Allergology International · doi:10.2332/allergolint.10-rai-0186 · Cited by 190
Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
Li, B., Li, W., Li, X., & Zhou, H. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161230142931 · Cited by 130
IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis
Gao, Y., Liu, Y., Yang, M., Guo, X., Zhang, M., Li, H., Li, J., & Zhao, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9259 · Cited by 79
Senescent cells suppress innate smooth muscle cell repair functions in atherosclerosis
Childs, B. G., Zhang, C., Shuja, F., Sturmlechner, I., Trewartha, S., Velasco, R. F., Baker, D. J., Li, H., & van Deursen, J. M. (2021) · Nature Aging · doi:10.1038/s43587-021-00089-5 · Cited by 76
Abston, E. D., Barin, J. G., Cihakova, D., Bucek, A., Coronado, M. J., Brandt, J. E., Bedja, D., Kim, J. B., Georgakopoulos, D., Gabrielson, K. L., et al. (2012) · Circulation: Heart Failure · doi:10.1161/circheartfailure.111.963769 · Cited by 69
“Mice were inoculated intraperitoneally (ip) with heart-passaged CVB3 on day 0 and hearts examined on day 10 post infection (pi) during acute myocarditis or day 35 pi during DCM.(4) rIL-33 (1 g/0.”
InfluentialImplication of IL-33 gene polymorphism in Chinese patients with Alzheimer's disease
Yu, J.-T., Song, J.-H., Wang, N.-D., Wu, Z.-C., Zhang, Q., Zhang, N., Zhang, W., Xuan, S.-Y., & Tan, L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.07.003 · Cited by 54
Metadata
- Authors
- Miller, A. M., Xu, D., Asquith, D. L., Denby, L., Li, Y., Sattar, N., Baker, A. H., McInnes, I. B., & Liew, F. Y.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2008-02-11
- Volume
- 205
- Issue
- 2
- Pages
- 339-346
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2168381900
- Cited by
- 642
- References
- 30
- FWCI
- 13.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.